Mei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mei Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Feng Cao
The Fourth Hospital of Hebei Medical University 1 Department of Radiation Oncology Shijiazhuang, China
8 shared publications - Guo Tian
The Fourth Hospital of Hebei Medical University 3 Department of Medical Record Shijiazhuang, China
8 shared publications - Lei Cao
Hebei General Hospital 2 Department of Geriatric Respiratory Shijiazhuang, China
8 shared publications - Lei Liu
The Fourth Hospital of Hebei Medical University 6 Department of Thoracic Surgery Shijiazhuang, China
8 shared publications - Liang Liu
The Fourth Hospital of Hebei Medical University 4 Analytical Cytology Laboratory, Cancer Institute Shijiazhuang, China
8 shared publications - Yawen Ding
The Fourth Hospital of Hebei Medical University 5 Clinical Laboratory Shijiazhuang, China
8 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S2. The overexpression and silencing of LIMS2 in lung adenocarcinoma cells.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S2. The overexpression and silencing of LIMS2 in lung adenocarcinoma cells.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Table S1. The relationship analysis between LIMS2 immunohistochemistry score and clinicopathological characteristics of lung adenocarcinoma patients.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Table S1. The relationship analysis between LIMS2 immunohistochemistry score and clinicopathological characteristics of lung adenocarcinoma patients.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S1. LIMS2 was decreased in lung adenocarcinoma cell lines.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S1. LIMS2 was decreased in lung adenocarcinoma cell lines.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Data from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Lung cancer is a highly malignant tumor and prone to recurrence and metastasis. Adenocarcinoma is the most common subtype. LIM zinc finger domain containing 2 (LIMS2) was reported to inhibit growth and metastasis of several tumors, whereas its role in lung adenocarcinoma remains unclear. This study aims to expound the function of LIMS2 in lung adenocarcinoma. The analysis from medical databanks showed that LIMS2 was lowly expressed in lung adenocarcinoma specimens, compared with the normal lung tissues, and our clinical data demonstrated that LIMS2 expression was associated with the tumor–node–metastasis stage of patients with lung adenocarcinoma. Gain- and loss-of-function experiments revealed that LIMS2 suppressed proliferation, invasion, migration, epithelial–mesenchymal transition of lung adenocarcinoma cells, delayed xenograft and orthotopic growth, and blocked distant metastasis and lymph infiltration in nude mice. The medium supernatant from LIMS2-overexpressed lung adenocarcinoma cells intercepted the activation of fibroblasts from lung cancer. The coimmunoprecipitation results demonstrated that an E3 ubiquitin ligase ring finger and CHY zinc finger domain containing 1 (RCHY1) interacted with LIMS2 and mediated its K48 ubiquitination and degradation. LIMS2 overexpression reversed the promoting effects of RCHY1 on proliferation, migration, and lung cancer–fibroblast activation of lung adenocarcinoma cells. In conclusion, decreased LIMS2 may mediate the tumor-promoting role of RCHY1 in lung adenocarcinoma cells.Implications:These findings may provide novel diagnostic markers and therapeutic targets for lung adenocarcinoma in clinic.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Lung cancer is a highly malignant tumor and prone to recurrence and metastasis. Adenocarcinoma is the most common subtype. LIM zinc finger domain containing 2 (LIMS2) was reported to inhibit growth and metastasis of several tumors, whereas its role in lung adenocarcinoma remains unclear. This study aims to expound the function of LIMS2 in lung adenocarcinoma. The analysis from medical databanks showed that LIMS2 was lowly expressed in lung adenocarcinoma specimens, compared with the normal lung tissues, and our clinical data demonstrated that LIMS2 expression was associated with the tumor–node–metastasis stage of patients with lung adenocarcinoma. Gain- and loss-of-function experiments revealed that LIMS2 suppressed proliferation, invasion, migration, epithelial–mesenchymal transition of lung adenocarcinoma cells, delayed xenograft and orthotopic growth, and blocked distant metastasis and lymph infiltration in nude mice. The medium supernatant from LIMS2-overexpressed lung adenocarcinoma cells intercepted the activation of fibroblasts from lung cancer. The coimmunoprecipitation results demonstrated that an E3 ubiquitin ligase ring finger and CHY zinc finger domain containing 1 (RCHY1) interacted with LIMS2 and mediated its K48 ubiquitination and degradation. LIMS2 overexpression reversed the promoting effects of RCHY1 on proliferation, migration, and lung cancer–fibroblast activation of lung adenocarcinoma cells. In conclusion, decreased LIMS2 may mediate the tumor-promoting role of RCHY1 in lung adenocarcinoma cells.Implications:These findings may provide novel diagnostic markers and therapeutic targets for lung adenocarcinoma in clinic.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S4. LIMS2 reversed the effects of RCHY1 on lung adenocarcinoma cells.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S4. LIMS2 reversed the effects of RCHY1 on lung adenocarcinoma cells.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S5. The transcriptome analysis of A549 cells with LIMS2 overexpression.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S5. The transcriptome analysis of A549 cells with LIMS2 overexpression.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S3. Downregulation of LIMS2 in lung adenocarcinoma cells promoted activation of lung cancer-fibroblasts.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S3. Downregulation of LIMS2 in lung adenocarcinoma cells promoted activation of lung cancer-fibroblasts.
- 6 February 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 24 (6) , 473-486
LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Lung cancer is a highly malignant tumor and prone to recurrence and metastasis. Adenocarcinoma is the most common subtype. LIM zinc finger domain containing 2 (LIMS2) was reported to inhibit growth and metastasis of several tumors, whereas its role in lung adenocarcinoma remains unclear. This study aims to expound the function of LIMS2 in lung adenocarcinoma. The analysis from medical databanks showed that LIMS2 was lowly expressed in lung adenocarcinoma specimens, compared with the normal lung tissues, and our clinical data demonstrated that LIMS2 expression was associated with the tumor–node–metastasis stage of patients with lung adenocarcinoma. Gain- and loss-of-function experiments revealed that LIMS2 suppressed proliferation, invasion, migration, epithelial–mesenchymal transition of lung adenocarcinoma cells, delayed xenograft and orthotopic growth, and blocked distant metastasis and lymph infiltration in nude mice. The medium supernatant from LIMS2-overexpressed lung adenocarcinoma cells intercepted the activation of fibroblasts from lung cancer. The coimmunoprecipitation results demonstrated that an E3 ubiquitin ligase ring finger and CHY zinc finger domain containing 1 (RCHY1) interacted with LIMS2 and mediated its K48 ubiquitination and degradation. LIMS2 overexpression reversed the promoting effects of RCHY1 on proliferation, migration, and lung cancer–fibroblast activation of lung adenocarcinoma cells. In conclusion, decreased LIMS2 may mediate the tumor-promoting role of RCHY1 in lung adenocarcinoma cells. Implications: These findings may provide novel diagnostic markers and therapeutic targets for lung adenocarcinoma in clinic.
- 6 February 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 24 (6) , 473-486
LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Lung cancer is a highly malignant tumor and prone to recurrence and metastasis. Adenocarcinoma is the most common subtype. LIM zinc finger domain containing 2 (LIMS2) was reported to inhibit growth and metastasis of several tumors, whereas its role in lung adenocarcinoma remains unclear. This study aims to expound the function of LIMS2 in lung adenocarcinoma. The analysis from medical databanks showed that LIMS2 was lowly expressed in lung adenocarcinoma specimens, compared with the normal lung tissues, and our clinical data demonstrated that LIMS2 expression was associated with the tumor–node–metastasis stage of patients with lung adenocarcinoma. Gain- and loss-of-function experiments revealed that LIMS2 suppressed proliferation, invasion, migration, epithelial–mesenchymal transition of lung adenocarcinoma cells, delayed xenograft and orthotopic growth, and blocked distant metastasis and lymph infiltration in nude mice. The medium supernatant from LIMS2-overexpressed lung adenocarcinoma cells intercepted the activation of fibroblasts from lung cancer. The coimmunoprecipitation results demonstrated that an E3 ubiquitin ligase ring finger and CHY zinc finger domain containing 1 (RCHY1) interacted with LIMS2 and mediated its K48 ubiquitination and degradation. LIMS2 overexpression reversed the promoting effects of RCHY1 on proliferation, migration, and lung cancer–fibroblast activation of lung adenocarcinoma cells. In conclusion, decreased LIMS2 may mediate the tumor-promoting role of RCHY1 in lung adenocarcinoma cells. Implications: These findings may provide novel diagnostic markers and therapeutic targets for lung adenocarcinoma in clinic.